|
|
||||||||
Ann Thorac Surg 2004;77:500-505
© 2004 The Society of Thoracic Surgeons
a Department of Surgery, Kurume University, Kurume, Japan
Accepted for publication June 6, 2003.
* Address reprint requests to Dr Hayashida, Department of Surgery, Kurume University, 67 Asahi-machi, Kurume, Japan 830-0011
e-mail: nobuhiko{at}med.kurume-u.ac.jp
| Abstract |
|---|
|
|
|---|
METHODS: Between 1989 and 2003, 18 patients with cirrhosis who underwent cardiac operations were identified. Their preoperative status and postoperative clinical results were assessed.
RESULTS: Ten patients were classified as having Child-Pugh class A cirrhosis, 7 as having class B cirrhosis, and 1 as having class C cirrhosis. Fifteen of 18 patients underwent cardiac surgery using cardiopulmonary bypass, and the remaining 3 patients with class B cirrhosis received coronary artery bypass grafting without cardiopulmonary bypass. In patients undergoing cardiopulmonary bypass, 60% of those with class A cirrhosis and 100% of those with class B cirrhosis and class C cirrhosis had postoperative major complications, including infection, respiratory failure, renal failure, bleeding, and gastrointestinal disorder. One of 3 patients (33%) with class B cirrhosis undergoing coronary artery bypass grafting without cardiopulmonary bypass had major complications. The overall postoperative mortality rate was 17%. Hospital mortality of patients with class A cirrhosis, class B cirrhosis, and class C cirrhosis undergoing cardiopulmonary bypass was 0%, 50%, and 100%, respectively. None of 3 patients with class B cirrhosis undergoing coronary artery bypass grafting without cardiopulmonary bypass died in this study.
CONCLUSIONS: Although the incidence of major complications was high, patients with Child-Pugh class A cirrhosis tolerated cardiac surgery satisfactorily. Patients with more advanced cirrhosis, however, may not be suitable for elective cardiac operations with cardiopulmonary bypass. Although our results are not conclusive, coronary artery bypass grafting without cardiopulmonary bypass can be an alternative therapeutic strategy for patients with advanced cirrhosis requiring surgical revascularization.
| Introduction |
|---|
|
|
|---|
| Patients and methods |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
|
|
|
|
| Comment |
|---|
|
|
|---|
Congestive heart failure owing to myocardial infarction, cardiomyopathy, rheumatic heart disease, or constrictive pericarditis increases hepatic venous pressure and decreases hepatic blood flow, with resulting congestive liver fibrosis and cirrhosis. Multiple medications for cardiac disorders and blood transfusion during prior cardiac surgery may also compromise liver function. Accordingly, a close association between cardiac and liver disorders exists, and we occasionally encounter patients with the pathognomonic features. Despite the circumstances, patients with cirrhosis are less frequently referred for elective open heart surgery because of their considerably compromised health status and decreased life expectancy.
Because the number of patients reported in the literature is small, and morbidity and mortality rates after cardiac surgery using CPB in patients with this comorbidity are considerably high [3, 4], definitive recommendations and indications for operation have not been conclusively shown. Recent studies demonstrated that although the incidence of postoperative complications was high, patients with mild cirrhosis tolerated open heart surgery well [3, 4]. Patients with more advanced cirrhosis, however, had significantly higher mortality rate (50% to 80%) after CPB [3, 4]. Moreover, the health status in such patients remained compromised even well after the operation [3]. Accordingly, it is generally agreed that elective cardiac operations using CPB are contraindicated in patients with moderate to severe cirrhosis (Child-Pugh class B or C cirrhosis). Our study also has shown that the mortality was 60% in patients with moderate to severe cirrhosis undergoing CPB. In contrast, none of the patients with Child-Pugh class B cirrhosis undergoing OPCAB died in this study. It has been well documented that the use of CPB triggers the production and release of numerous vasoactive substances and cytotoxic chemicals that affect coagulopathy, vascular resistance, vascular permeability, fluid balance, and major organ function [11]. Other contributing factors, such as hypothermia, hemodilution, and hypoperfusion during CPB, also may be responsible for the morbidity and mortality after operation [12]. The avoidance of CPB use, therefore, may theoretically improve postoperative clinical outcome by preventing its adverse side effects, particularly in patients with compromised organ function. Although the technique is not indicated in all patients requiring cardiac surgical interventions, OPCAB can be an alternative therapeutic strategy for patients with moderate to severe cirrhosis requiring surgical revascularization. However, because little is known about whether this technique improves postoperative clinical outcome in patients with moderate to severe cirrhosis, further investigations including more patients are required for the universal application.
Similar to earlier reports [3, 4], the incidence of postoperative fluid retention, characterized by edema, ascites, pericardial effusion, and pleural effusion, was considerably high and the management was troublesome in most cases. Poor nutritional status, sodium retention, and portopulmonary hypertension in cirrhotic patients may be responsible for the abnormalities [13]. Several studies have shown that renal responsiveness to atrial natriuretic peptides was blunted despite baseline elevation of its level in cirrhotic patients [14, 15]. The resistance to natriuretic action, which is similarly seen in patients with congestive heart failure [15], may lead to water and sodium retention. Moreover, because biologic activity of endogenous atrial natriuretic peptides has been reported to decrease after CPB [16], the edematous status may worsen after cardiac surgery. Because natriuretic effects of synthetic urodilatin, an atrial natriuretic peptide, have been proven even in cirrhosis with ascites [17], perioperative use of this agent may improve clinical outcome after cardiac operations.
Previous reports have shown that the higher mortality was not attributable to impaired cardiac function, but to an increased susceptibility to infections, gastrointestinal complications, and bleeding [3, 4]. Similar to these reports, the present study also demonstrated the higher prevalence of infections, such as mediastinitis and septicemia, probably related to poor nutritional state and excessive mediastinal bleeding requiring reexploration. In a recent report [1], preoperative levels of serum cholinesterase, a hepatocyte secretion enzyme, have been demonstrated to be an independent predictor of mortality in patients with liver dysfunction undergoing cardiac surgery. Because cholinesterase activity correlates with hepatic protein synthesis rate, the values are considered to be an index of hepatic functional reserve [18]. Markedly lower values of cholinesterase and albumin to globulin ratio observed in our patient population would represent malnutritional status and reduced hepatic functional reserve. Assessment and optimization of perioperative nutritional status thus are essential for an improvement of postoperative clinical outcomes in such patients. In patients with end-stage cardiac failure requiring ventricular assist device, a low preoperative bilirubin level has been shown to be the only significant predictor for survival [2]. In the present study, although the results are not conclusive because of the small sample size, patients with postoperative major complications tended to have higher preoperative bilirubin levels (1.7 ± 0.8 versus 0.9 ± 0.4 mg/dL; p = 0.04). Besides the Child-Pugh score, one must take preoperative bilirubin level per se into consideration for patient selection and perioperative management. Perioperative ammonia concentration also should be controlled meticulously because patients with portal hypertension are particularly prone to develop hyperammonemia [19]. We control its level by eliminating protein from the diet, removing nitrogen from the gastrointestinal tract by cathartics and enemas, and administering intestinal antibiotics.
In summary, although major morbidity was high, patients with Child-Pugh class A cirrhosis tolerated cardiac surgery satisfactorily. In patients with more advanced cirrhosis, such as Child-Pugh class B and C cirrhosis, however, postoperative mortality was unacceptably high, and this patient subgroup may not be suitable for elective cardiac operations with CPB. Although our results are not conclusive because of the small patient number, OPCAB can be an alternative therapeutic strategy for patients with advanced cirrhosis requiring surgical revascularization.
| Acknowledgments |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. Vanhuyse, P. Maureira, E. Portocarrero, N. Laurent, M. Lekehal, J.-P. Carteaux, and J.-P. Villemot Cardiac surgery in cirrhotic patients: results and evaluation of risk factors Eur J Cardiothorac Surg, January 26, 2012; (2012) ezr320v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lima, E. R. Nowicki, C. M. Miller, K. Hashimoto, N. G. Smedira, and G. V. Gonzalez-Stawinski Outcomes of Simultaneous Liver Transplantation and Elective Cardiac Surgical Procedures Ann. Thorac. Surg., November 1, 2011; 92(5): 1580 - 1584. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. GUNDLING, H. SEIDL, F. SCHMIDTLER, N. LOFFLER, I. STRASSEN, P. WOLF, C. PEHL, T. SCHMIDT, and W. SCHEPP Nonhepatic Cancer in Liver Cirrhosis: A Retrospective Study of Prevalence, Complication Rate after Specific Oncological Treatment, Follow-up and Prognostic Predictors of Outcome in 354 Patients with Cirrhosis Anticancer Res, September 1, 2011; 31(9): 2931 - 2938. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marui, T. Kimura, S. Tanaka, S. Miwa, K. Yamazaki, K. Minakata, T. Nakata, T. Ikeda, Y. Furukawa, T. Kita, et al. Coronary Revascularization in Patients With Liver Cirrhosis Ann. Thorac. Surg., May 1, 2011; 91(5): 1393 - 1399. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Y. H. Lip, H.-F. Tse, and A. J. Stewart Coats Perioperative evaluation for cardiac surgery ODR Cardiology, January 1, 2011; 1(1): med-9780199568093-div1-01 - med-9780199568093-div1-01. [Full Text] |
||||
![]() |
A. Modi, H. A. Vohra, and C. W. Barlow Do patients with liver cirrhosis undergoing cardiac surgery have acceptable outcomes? Interact CardioVasc Thorac Surg, November 1, 2010; 11(5): 630 - 634. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Jeong, J. Sung Kim, K.-H. Kim, and H. Ahn Left atrial metastasis from hepatocellular carcinoma with liver cirrhosis Interact CardioVasc Thorac Surg, November 1, 2010; 11(5): 703 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thielmann, A. Mechmet, M. Neuhauser, D. Wendt, P. Tossios, A. Canbay, P. Massoudy, and H. Jakob Risk prediction and outcomes in patients with liver cirrhosis undergoing open-heart surgery Eur J Cardiothorac Surg, November 1, 2010; 38(5): 592 - 599. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Morisaki, M. Hosono, Y. Sasaki, S. Kubo, H. Hirai, S. Suehiro, and T. Shibata Risk Factor Analysis in Patients With Liver Cirrhosis Undergoing Cardiovascular Operations Ann. Thorac. Surg., March 1, 2010; 89(3): 811 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Gelow, A. S. Desai, C. P. Hochberg, J. N. Glickman, M. M. Givertz, and J. C. Fang Clinical Predictors of Hepatic Fibrosis in Chronic Advanced Heart Failure Circ Heart Fail, January 1, 2010; 3(1): 59 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-B. Hsu, C.-I. Chang, F.-Y. Lin, N.-K. Chou, N.-H. Chi, S.-S. Wang, and S.-H. Chu Heart transplantation in patients with liver cirrhosis Eur J Cardiothorac Surg, August 1, 2008; 34(2): 307 - 312. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Iino, S. Tomita, S. Yamaguchi, and G. Watanabe Successful aortic valve replacement using dilutional ultrafiltration during cardiopulmonary bypass in a patient with Child-Pugh class C cirrhosis Interact CardioVasc Thorac Surg, April 1, 2008; 7(2): 331 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-B. Hsu, F.-Y. Lin, N.-K. Chou, W.-J. Ko, N.-H. Chi, and S.-S. Wang Heart transplantation in patients with extreme right ventricular failure Eur J Cardiothorac Surg, September 1, 2007; 32(3): 457 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsukuma, H. Yamaguchi, and M. Hamawaki Stanford Type A Aortic Dissection with Child B Liver Cirrhosis Asian Cardiovasc Thorac Ann, June 1, 2007; 15(3): e38 - e40. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. An and Y.-B. Xiao The preventative role of growth hormone on acute liver injury induced by cardiopulmonary bypass in a rat model Eur J Cardiothorac Surg, June 1, 2007; 31(6): 1037 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. An, Y.-B. Xiao, and Q.-J. Zhong Open-heart surgery in patients with liver cirrhosis Eur J Cardiothorac Surg, June 1, 2007; 31(6): 1094 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ben Ari, E. Elinav, A. Elami, and I. Matot Off-pump coronary artery bypass grafting in a patient with Child class C liver cirrhosis awaiting liver transplantation Br. J. Anaesth., October 1, 2006; 97(4): 468 - 472. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Iwasaki, T. Shirakusa, K. Okabayashi, K. Inutsuka, S. Yoneda, S. Yamamoto, and T. Shiraisi Lung cancer surgery in patients with liver cirrhosis. Ann. Thorac. Surg., September 1, 2006; 82(3): 1027 - 1032. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N.K. Odim, J. Wu, H. Laks, A. Banerji, and S. Drant Cardiac Surgery in Children With End-Stage Liver Disease Awaiting Liver Transplantation Ann. Thorac. Surg., February 1, 2006; 81(2): 697 - 700. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Lin, F.-Y. Lin, S.-S. Wang, H.-Y. Yu, and R.-B. Hsu Cardiac Surgery in Patients With Liver Cirrhosis Ann. Thorac. Surg., May 1, 2005; 79(5): 1551 - 1554. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hanvesakul, R. Deshpande, C. S. Carr, and N. Akbar Aspergillus aortitis: a cause for aortic perforation in a patient following combined aortic valve surgery and liver transplantation Interact CardioVasc Thorac Surg, December 1, 2004; 3(4): 544 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Hessel II Abdominal Organ Injury After Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2004; 8(3): 243 - 263. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |